CompanyGraph
What stands out
- Pays more per share than it earned over the last twelve months
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleRevenue is $965.87M, above the global median of $558.46M
- PositionGross margin is 9.3%, lower than 95% of its Medical Devices peers (median 62.5%)
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
What stands out
- Pays more per share than it earned over the last twelve months
Dividends view
Yield
1.45%
Annual Rate
CNY 0.12Paid annual
Payout Ratio
244.0%High
Payback Period
71.6 yr
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
3.97BCNY591.98M · vs all stocks (USD)
Trailing P/E
168.60xvs Medical Devices peers
Revenue (TTM)
6.47BCNY965.87M · vs all stocks (USD)
Profit Margin
0.41%vs Medical Devices peers
52-Week Change
-22.73%vs all stocks
Market Capitalization
3.97BCNY591.98M · vs all stocks (USD)
Enterprise Value
6.37BCNY951.02M · vs all stocks (USD)
Trailing P/E
168.60xvs Medical Devices peers
Price to Sales (TTM)
0.6129xvs Medical Devices peers
Price to Book (MRQ)
2.25xvs Medical Devices peers
Enterprise to Revenue
0.9850xvs Medical Devices peers
Enterprise to EBITDA
47.50xvs Medical Devices peers
Gross Margin
9.31%vs Medical Devices peers
Profit Margin
0.41%vs Medical Devices peers
Operating Margin
1.74%vs Medical Devices peers
Return on Assets (TTM)
0.90%vs Medical Devices peers
Return on Equity (TTM)
0.65%vs Medical Devices peers
Revenue (TTM)
6.47BCNY965.87M · vs all stocks (USD)
Revenue per Share (TTM)
12.50CNYUpdated Sep 19, 2026Quarterly Revenue Growth
-17.70%vs Medical Devices peers
Gross Profit (TTM)
590.88MCNY88.17M · vs all stocks (USD)
EBITDA (TTM)
307.07MCNY45.82M · vs all stocks (USD)
Net Income (TTM)
26.76MCNY3.99M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-84.50%vs Medical Devices peers
Operating Cash Flow (TTM)
593.27MCNY88.53M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-158.16MCNY-23.60M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.1220CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
1.45%vs all stocks
Payout Ratio
244.00%vs Medical Devices peers
Minority Interest (Equity)
43.52MCNYFY2025 · Dec 31, 2025Revenue
6.99BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
6.25BCNYFY2025 · Dec 31, 2025Gross Profit
741.85MCNYFY2025 · Dec 31, 2025Operating Income
212.51MCNY31.71M · vs all stocks (USD)
Pre-tax Income
92.21MCNYFY2025 · Dec 31, 2025Income Tax Expense
27.61MCNYFY2025 · Dec 31, 2025Net Income
64.60MCNYFY2025 · Dec 31, 2025EBIT
126.56MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
307.07MCNYFY2025 · Dec 31, 2025Research & Development
10.35MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
194.34MCNYFY2025 · Dec 31, 2025Other Operating Expenses
22.12MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.33MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
34.35MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
486.79MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
486.79MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
64.60MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
3.55MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
442.23MCNYFY2025 · Dec 31, 2025Free Cash Flow
410.02MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
659.72MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
64.60MCNYFY2025 · Dec 31, 2025Other Non-cash Items
38.82MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
235.25MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
103.57MCNYFY2025 · Dec 31, 2025Capital Expenditures
-32.21MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-32.21MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
1.03BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-1.50BCNYFY2025 · Dec 31, 2025Common Dividends Paid
-67.25MCNYFY2025 · Dec 31, 2025Other Financing Charges
-73.22MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-616.17MCNYFY2025 · Dec 31, 2025Shares Outstanding
470.60MSharesUpdated Sep 19, 2026Float Shares
321.84MSharesUpdated Sep 19, 2026% Held by Insiders
53.72%vs all stocks
% Held by Institutions
16.73%vs all stocks
Total Cash (MRQ)
618.96MCNY92.36M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.9440CNYUpdated Sep 19, 2026Total Debt (MRQ)
1.43BCNY212.71M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.5707xvs Medical Devices peers
Current Ratio (MRQ)
1.49xvs Medical Devices peers
Book Value per Share (MRQ)
3.75CNYUpdated Sep 19, 2026Total Assets
6.34BCNY946.06M · vs all stocks (USD)
Total Current Assets
5.49BCNYFY2025 · Dec 31, 2025Total Liabilities
3.79BCNYFY2025 · Dec 31, 2025Total Non-current Assets
845.87MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
161.43MCNYFY2025 · Dec 31, 2025Total Current Liabilities
3.63BCNYFY2025 · Dec 31, 2025Cash
659.72MCNYFY2025 · Dec 31, 2025Cash Equivalents
71.44MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
731.15MCNYFY2025 · Dec 31, 2025Accounts Receivable
1.43BCNYFY2025 · Dec 31, 2025Inventory
2.51BCNYFY2025 · Dec 31, 2025Accounts Payable
2.10BCNYFY2025 · Dec 31, 2025Short-term Debt
979.76MCNYFY2025 · Dec 31, 2025Other Current Liabilities
16.51MCNYFY2025 · Dec 31, 2025Long-term Debt
157.78MCNYFY2025 · Dec 31, 2025Common Stock (Book)
470.60MCNYFY2025 · Dec 31, 2025Retained Earnings
851.04MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
2.55BCNY380.62M · vs all stocks (USD)
Treasury Stock
50.10MCNYFY2025 · Dec 31, 202552-Week Low
7.89CNYUpdated Sep 19, 202652-Week High
13.13CNYUpdated Sep 19, 202652-Week Change
-22.73%vs all stocks
50-Day MA
8.72CNYUpdated Sep 19, 2026200-Day MA
10.15CNYUpdated Sep 19, 2026Avg 10-Day Volume
2.24MSharesUpdated Sep 19, 2026Avg 30-Day Volume
3.72MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.0500CNYUpdated Sep 19, 20262 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
How is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Gross margin is 9.3%, lower than 95% of its Medical Devices peers (median 62.5%)Significant
Gross margin: 0.09Industry median: 0.62Industry P5: 0.28Peers compared: 100
P/E ratio is 168.6×, higher than 95% of its Medical Devices peers (median 29.87×)Significant
P/E ratio: 168.6Industry median: 29.87Industry P95: 135.655Peers compared: 100
Structural Tensions
Pays more per share than it earned over the last twelve monthsSignificant
Payout Ratio: 2.44Dividend per Share: 0.12Earnings per Share: 0.05
Financial Health
Altman Z-Score 2.34: grey zoneSignificant
Altman Z-Score: 2.34
High earnings qualityNotable
Earnings Quality Score: 1.74
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Revenue is $965.87M, above the global median of $558.46MNotable
Revenue (USD): 965,868,427.377Global Median: 558,459,881.051
Companies that share the same coordination system — how they create, deliver, or capture value.
SS Innovations International, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Wohua Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Phathom Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
OrthoPediatrics Corp.
Tier 1ProductionApproval-Gated PipelineRule
Altimmune, Inc.
Tier 1ProductionApproval-Gated PipelineRule
CytomX Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Beijing Bohui Innovation Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Neptunus Bioengineering Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Weixinkang Medicine Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aquestive Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Systems Technology Inc.
2 interpretationsClose Below 40W SMA With ProfitabilityIndustry-Benchmarked Return on Capital Elevated
Pan German Universal Motors
2 interpretationsClose Below 40W SMA With ProfitabilityIndustry-Benchmarked Return on Capital Elevated
Transcontinental Inc.
1 interpretationClose Below 40W SMA With Profitability